The resumption of 737 MAX production comes at a critical time for Boeing, as the company continues to face challenges related to the aircraft model's safety and certification. The 737 MAX was grounded worldwide in March 2019 following two fatal crashes that claimed the lives of 346 people. Since then, Boeing has been working closely with regulatory authorities to address the issues that led to the crashes and to ensure the aircraft's safe return to service.Revolutionary Single-Layer Film Eliminates Helmet Changes, Enhancing Driver Safety and Performance LAS VEGAS , Dec. 11, 2024 /PRNewswire/ -- Racing Optics®, the global leader in high-performance tearoff visor film technology, proudly unveils its latest innovation: the Twilight Tearoff . This groundbreaking single-layer tearoff is engineered to elevate driver visibility during late-afternoon and early-evening races, providing superior glare reduction and contrast enhancement. The Twilight Tearoff redefines race-day performance by allowing drivers to maintain focus and adapt seamlessly to changing light conditions, eliminating the need for disruptive helmet changes. This innovation represents a significant leap forward in racing vision technology, delivering immediate and measurable benefits to professional drivers and teams alike. "The Twilight Tearoff solves one of racing's most persistent challenges—ensuring optimal visibility as lighting transitions rapidly during twilight races," said Chris Colton , Chief Applications Engineer at Racing Optics . "Our dedication to driver safety and performance drives every innovation, and the Twilight Tearoff is no exception." Transforming Racing at Twilight Racing teams are already embracing the Twilight Tearoff as a game-changing solution for twilight and low-light racing conditions. One racing team manager shared their experience: "In a recent twilight race, the Twilight Tearoff gave our drivers unmatched visual clarity. Transitioning from glaring sunlight to artificial lighting without pausing to change helmets was a decisive advantage that kept us competitive." By streamlining the driver experience, the Twilight Tearoff enhances safety and helps maintain uninterrupted race momentum—a critical edge in the high-stakes world of motorsports. Exclusive Debut at PRI Show 2024 The Twilight Tearoff will make its debut at the Performance Racing Industry (PRI) Show , held December 12–14, 2024, in Indianapolis, Indiana . This highly anticipated event marks Racing Optics' 25th anniversary , celebrating a legacy of trailblazing innovations in motorsports safety and performance. Availability The Twilight Tearoff is now available for purchase at RacingOptics.com and through authorized dealers. Teams and drivers looking to gain a competitive edge are encouraged to explore this latest advancement. About Racing Optics For 25 years, Racing Optics has led the field in racing vision technology, delivering innovative solutions that enhance safety and performance. With a commitment to collaboration and innovation, the company continues to push the boundaries of motorsports protective equipment. For additional information, please visit RacingOptics.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/racing-optics-introduces-game-changing-twilight-tearoff-to-enhance-visibility-in-low-light-racing-conditions-302329546.html SOURCE Racing Optics, Inc. Stay Informed: Subscribe to Our Newsletter TodayAs we reflect on this extraordinary tale of kindness and generosity, let us be inspired to reach out to those in need, to offer a helping hand without expecting anything in return. May we all strive to be like Zhang, the unsung hero of Shanxi, whose simple act of compassion changed a life and touched the hearts of many.jili bet 888 。

In the midst of bustling cities and serene landscapes, the bond between South Koreans and the Chinese grows stronger with each passing day, fueled by a mutual love for culture, exploration, and connection. The visa-free month may have started as a simple policy change, but it has blossomed into a beautiful journey of friendship and discovery for both South Koreans and Chinese alike.Manchester City, despite their domestic dominance in recent years, have encountered tough opposition in their group stage matches. Pep Guardiola's side have faced several strong teams, testing their mettle and resilience. Whether it's facing the defensive prowess of Atletico Madrid or the attacking flair of Liverpool, Manchester City have had to dig deep to secure results. The battle for survival in the group stage has been intense, with every point crucial in determining the team's fate.As fans eagerly await further announcements regarding both the Pepsi collaboration and the "gourd gift box," one thing is certain - "Black Myth: Wukong" is shaping up to be a game that will leave a lasting impact on the gaming industry. With its stunning visuals, engaging gameplay, and now exciting partnerships with iconic brands like Pepsi, the game is set to take players on an unforgettable journey through a world inspired by Chinese mythology.

Canadian Green Party leader: Trump's 51st state 'joke' is 'not funny'Ana Navarro Defends Pam Bondi for Trump’s AG: 'She’s Not a Kook'In the Ice Zone, figure skaters and speed skaters will captivate audiences with their grace and skill on the ice. From the artistry of figure skating to the lightning-fast speed of short track racing, athletes in the Ice Zone will showcase a wide range of talents and techniques. The atmosphere of the arena will be charged with excitement as competitors vie for medals in these elegant and thrilling events.

In the midst of a recent slump in form, tensions rising within the team, and poor performances on the pitch, star forward Kylian Mbappe has taken the proactive step of rooting out the source of the issue by calling for a team meeting to address the situation at hand.Title: Visa-Free Month: How South Koreans Are Winning over Chinese Hearts

In his statement, Zelensky reiterated Ukraine's commitment to democracy and the rule of law, emphasizing the need for leaders to accept electoral outcomes and work towards national unity and progress. He expressed confidence in the resilience of American democracy and the ability of the United States to overcome its current political divisions and challenges.Biden calls for Assad to be 'held accountable'

As the global financial industry continues to undergo rapid transformation, Eric Trump's views on the irrelevance of modern banks resonated with many who recognize the limitations of traditional financial institutions in the digital age. With the rise of decentralized finance (DeFi) platforms and the increasing popularity of cryptocurrencies like Bitcoin and Ethereum, it is becoming evident that the current banking system is due for a significant overhaul.

Caleb Temiloluwa Adewole, a first-class graduate from FUTA, achieved academic excellence with a CGPA of 4.85/5.00, ranking as the second-best student in his class Overcoming challenges such as balancing leadership roles and financial constraints, Caleb attributes his success to discipline, active recall, and spaced repetition study techniques His journey from scoring high in UTME and Post-UTME to receiving prestigious scholarships shows his dedication and resilience in pursuit of becoming a world-class engineer CHECK OUT: Learn at Your Own Pace! Our Flexible Online Course allows you to fit copywriting skills development around your busy schedule. Enroll Now! In Federal University of Technology , Akure (FUTA), where dreams are often forged from sheer will and determination, Caleb Temiloluwa Adewole emerged as a beacon of academic excellence. His story, much like a river carving its path through mountains, is one of resilience, unwavering faith, and an insatiable thirst for knowledge. Caleb Temiloluwa Adewole first-class graduate Graduating with a CGPA of 4.85/5.00, he stood as the second-best student in his class, a testament to his relentless pursuit of greatness. Read also Graduate of Ajayi Crowther University completes degree with CGPA of 4.95, shares proudest moments PAY ATTENTION : Standing out in social media world? Easy! "Mastering Storytelling for Social Media" workshop by Legit.ng. Join Us Live! In an interview with Legit.ng , Caleb said he had early academic victories in 2017. “I never expected to score as high as 339/400. I just wanted to do well in the exam; I didn't have a specific goal in mind. I was the highest in my secondary school that year, and that record remains unbroken even seven years after I graduated! I'm also proud of my 2017 Post-UTME result: I scored a whopping 96%, getting 24 questions right out of the 25 multiple-choice questions. I like to think that I should have scored 100%. I recall that there was a math question that had no correct answer, and I had to just pick one of the four options which I assumed to be the answer. That could have been the only question I got wrong. In university, I had very high scores in notoriously difficult courses. There was one particular course where I had 98%. When the rumour went out that someone scored 98%, I thought the person was one of my friends, who was known to be very passionate about that course; I never expected it would be me. I was amazed when I saw the result!” Read also FUTA graduate who overcame failing a course in year two to bag first class shares her study hack Challenges Along the Way Yet, these numbers were but milestones on a journey defined by meticulous preparation and an unyielding spirit. As Caleb navigated the labyrinth of higher education , he encountered challenges that tested his resolve. “One challenge I faced had to do with balancing my academics with leadership responsibilities. In my third year at FUTA, I was appointed as the President of my fellowship. This role required a lot of sacrifices and dedication. I needed to keep maintaining excellent grades because of my reputation in the department and needed to also do well in leadership. Another challenge was financial. There were times I was really broke and that affected me a bit.” Nigerian Student Academic Excellence In these moments of adversity, Caleb's character was forged, his resilience becoming a symbol of hope for those who followed. “First, God made everything possible. I was excellent because God made me excellent. Also, I think my love for excellence was also key. I have always loved excellence—when I was younger, I prayed about it a lot. Then there is the place of discipline. I wouldn't have been able to achieve high standards if I wasn't disciplined enough. Studying requires discipline—putting away all distractions and focusing for the study period. When I was President, I would delegate responsibilities to my fellow executives when it was difficult to meet up due to tight schedules. I had a very supportive team. This made the work easy. In addition, I used to take advantage of free times to study. As I used my phone for study a lot, I didn't have to take my books everywhere. For times when I was broke, the scholarships I won came through a lot.” Read also Lead City University first class graduate gets plot of land worth N2m, live turkey, N100,000 Study Techniques for Academic Success The secret to Caleb's success lay in the habits he diligently cultivated. Techniques like active recall and spaced repetition became his trusted allies. He told Legit.ng : “One of the habits that helped me succeed academically is the practice of doing active recall and spaced repetition. Active recall involves quizzing oneself based on a study material rather than passively reading and re-reading the material. Spaced repetition, on the other hand, involves strategically spacing out study sessions on a particular topic or subject. Put simply, it means pushing forward what you already know and reviewing it later in the future while reviewing what you don't know more frequently till you can easily recall it. I found a software called "Anki" that implemented these techniques, and I religiously used it from my 3rd year till my final-year, 500 level. Another habit was studying past exam papers. In my school (or more specifically, my department), past questions are a thing! When preparing for exams, my friends would bring past exam questions to me, and I would attempt to answer (or solve) them. One other thing I want to mention is the place of seniors or mentors. I had people in higher levels whom I looked up to. I would ask them questions and get useful materials for each semester. This was particularly instrumental to my academic success.” Read also Lead City University student who studied for three hours daily graduates with excellent result Caleb’s academic excellence did not go unnoticed. Scholarships from the Petroleum Technology Development Fund (PTDF) and a joint venture between the Nigeria National Petroleum Corporation ( NNPC ) and Chevron Nigeria Limited were testaments to his hard work and dedication. These accolades were more than financial aids; they were affirmations of his capabilities and the promise of what he could achieve. Now, his eyes are set on the horizon, where dreams of becoming a world-class engineer beckon. With a foundation built on excellence and a heart full of aspirations, he seeks to further his education abroad, positioning himself for global opportunities. To those who aspire to academic excellence, Caleb offers a simple yet profound piece of advice: believe in your potential. “You need an excellence mindset. Believe that you can be excellent academically and seek ways to get better in your studies. Experiment with different methods of studying and pick which one gives you the best result. I think some people discover what works for them too late. So start early! Focus on results and pick the process that gives you the best result. I am rooting for you!” Read also Against all odds, graduate of Federal University of Gusau finishes his degree with first class Graduate of FUGUS Finishes Degree with First Class Legit.ng earlier reported that Mamud Abdulmajeed achieved remarkable academic success . Graduating with a first-class degree in Microbiology and a CGPA of 4.56, Abdulmajeed's journey is a testament to hard work, discipline, and the support of his family and friends. PAY ATTENTION : Legit.ng Needs Your Opinion! That's your chance to change your favourite news media. Fill in a short questionnaire Source: Legit.ngNone

WASHINGTON (AP) — One year after the Jan. 6, 2021 , U.S. Capitol attack, Attorney General Merrick Garland said the Justice Department was committed to holding accountable all perpetrators “at any level” for “the assault on our democracy.” That bold declaration won't apply to at least one person: Donald Trump. Special counsel Jack Smith's move on Monday to abandon the federal election interference case against Trump means jurors will likely never decide whether the president-elect is criminally responsible for his attempts to cling to power after losing the 2020 campaign. The decision to walk away from the election charges and the separate classified documents case against Trump marks an abrupt end of the Justice Department’s unprecedented legal effort that once threatened his liberty but appears only to have galvanized his supporters. The abandonment of the cases accusing Trump of endangering American democracy and national security does away with the most serious legal threats he was facing as he returns to the White House. It was the culmination of a monthslong defense effort to delay the proceedings at every step and use the criminal allegations to Trump's political advantage, putting the final word in the hands of voters instead of jurors. “We always knew that the rich and powerful had an advantage, but I don’t think we would have ever believed that somebody could walk away from everything,” said Stephen Saltzburg, a George Washington University law professor and former Justice Department official. “If there ever was a Teflon defendant, that’s Donald Trump.” While prosecutors left the door open to the possibility that federal charges could be re-filed against Trump after he leaves office, that seems unlikely. Meanwhile, Trump's presidential victory has thrown into question the future of the two state criminal cases against him in New York and Georgia. Trump was supposed to be sentenced on Tuesday after his conviction on 34 felony counts in his New York hush money case , but it's possible the sentencing could be delayed until after Trump leaves office, and the defense is pushing to dismiss the case altogether. Smith's team stressed that their decision to abandon the federal cases was not a reflection of the merit of the charges, but an acknowledgement that they could not move forward under longstanding Justice Department policy that says sitting presidents cannot face criminal prosecution. Trump's presidential victory set “at odds two fundamental and compelling national interests: On the one hand, the Constitution’s requirement that the President must not be unduly encumbered in fulfilling his weighty responsibilities . . . and on the other hand, the Nation’s commitment to the rule of law,” prosecutors wrote in court papers. The move just weeks after Trump's victory over Vice President Kamala Harris underscores the immense personal stake Trump had in the campaign in which he turned his legal woes into a political rallying cry. Trump accused prosecutors of bringing the charges in a bid to keep him out of the White House, and he promised revenge on his perceived enemies if he won a second term. “If Donald J. Trump had lost an election, he may very well have spent the rest of his life in prison,” Vice President-elect JD Vance, wrote in a social media post on Monday. “These prosecutions were always political. Now it’s time to ensure what happened to President Trump never happens in this country again.” After the Jan. 6 attack by Trump supporters that left more than 100 police officers injured, Republican leader Mitch McConnell and several other Republicans who voted to acquit Trump during his Senate impeachment trial said it was up to the justice system to hold Trump accountable. The Jan. 6 case brought last year in Washington alleged an increasingly desperate criminal conspiracy to subvert the will of voters after Trump's 2020 loss, accusing Trump of using the angry mob of supporters that attacked the Capitol as “a tool” in his campaign to pressure then-Vice President Mike Pence and obstruct the certification of Democrat Joe Biden's victory. Hundreds of Jan. 6 rioters — many of whom have said they felt called to Washington by Trump — have pleaded guilty or been convicted by juries of federal charges at the same courthouse where Trump was supposed to stand trial last year. As the trial date neared, officials at the courthouse that sits within view of the Capitol were busy making plans for the crush of reporters expected to cover the historic case. But Trump's argument that he enjoyed absolute immunity from prosecution quickly tied up the case in appeals all the way up to the Supreme Court. The high court ruled in July that former presidents have broad immunity from prosecution , and sent the case back to the trial court to decide which allegations could move forward. But the case was dismissed before the trial court could get a chance to do so. The other indictment brought in Florida accused Trump of improperly storing at his Mar-a-Lago estate sensitive documents on nuclear capabilities, enlisting aides and lawyers to help him hide records demanded by investigators and cavalierly showing off a Pentagon “plan of attack” and classified map. But U.S. District Judge Aileen Cannon dismissed the case in July on grounds that Smith was illegally appointed . Smith appealed to the Atlanta-based 11th U.S. Circuit Court of Appeals, but abandoned that appeal on Monday. Smith's team said it would continue its fight in the appeals court to revive charges against Trump's two co-defendants because “no principle of temporary immunity applies to them.” In New York, jurors spent weeks last spring hearing evidence in a state case alleging a Trump scheme to illegally influence the 2016 election through a hush money payment to a porn actor who said the two had sex. New York prosecutors recently expressed openness to delaying sentencing until after Trump's second term, while Trump's lawyers are fighting to have the conviction dismissed altogether. In Georgia, a trial while Trump is in office seems unlikely in a state case charging him and more than a dozen others with conspiring to overturn his 2020 election loss in the state. The case has been on hold since an appeals court agreed to review whether to remove Fulton County District Attorney Fani Willis over her romantic relationship with the special prosecutor she had hired to lead the case. Associated Press reporter Lisa Mascaro in Washington contributed.

SAN DIEGO (AP) — Mark Few liked what he saw unfold at San Diego State's Viejas Arena when his No. 3 Gonzaga Bulldogs made their first foray outside of Spokane, Washington, this season. A double-digit victory in a packed, loud arena. Toughness from a deep, experienced lineup that once again is driven to win an elusive national championship. And, peeking a few seasons ahead, he saw an SDSU team that he views more as a future Pac-12 partner than rival. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.One of the key drivers propelling China's economic growth in 2024 is its continued emphasis on technological innovation. With a strong focus on emerging technologies such as artificial intelligence, blockchain, and renewable energy, China is positioning itself as a global leader in innovation. This emphasis on technological advancement not only fosters economic growth but also enhances productivity and competitiveness across various industries.Chris Evans Makes a Return as Captain America in "Avengers 5"

BOSTON--(BUSINESS WIRE)--Dec 8, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVYTM (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additional evidence of the benefits of eradicating transfusion requirements for people with transfusion-dependent beta thalassemia and vaso-occlusive crises for those with sickle cell disease,” said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Catholic University of the Sacred Heart of Rome, Director of the Department of Pediatric Hematology and Oncology at Bambino Gesù Children’s Hospital, Chair of Vertex’s TDT Program Steering Committee, and Presenting Author of the CASGEVY clinical data at ASH. “With median follow-up around three years there is strong evidence for the durability of these beneficial effects following treatment with CASGEVY.” “CASGEVY is changing the outlook for people living with sickle cell disease and beta thalassemia, with these data reinforcing the immense clinical value a durable one-time therapy can provide to patients,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We have a strong commitment to build on our progress in bringing CASGEVY to patients around the world.” New long-term follow-up data presented from the CASGEVY trials Vertex had seven abstracts accepted at the ASH annual meeting as outlined below: Progress in bringing CASGEVY to patients around the world CASGEVY is approved for both SCD and TDT in the U.S., the European Union, Great Britain, Canada, Switzerland, Bahrain and the Kingdom of Saudi Arabia, and Vertex plans to make submissions in the United Arab Emirates and Kuwait. More than 45 authorized treatment centers have been activated globally to support the delivery of CASGEVY, and more than 40 patients have had a first cell collection. Vertex is continuing to work with reimbursement authorities to secure sustainable access for patients. Through this work, Vertex has agreements to provide CASGEVY in multiple countries, including the U.S., England (TDT), Austria, Bahrain and the Kingdom of Saudi Arabia, and continues to make strong progress in others, including positive Health Technology Assessments (HTAs) in Canada for both diseases and advancing access negotiations for SCD patients in England. In the U.S., Vertex recently secured an industry-first, voluntary agreement with the Centers for Medicare & Medicaid Services (CMS) on a single outcomes-based arrangement available to all state Medicaid programs to ensure broad and equitable access to CASGEVY. To support this progress on patient access and growing patient demand, Vertex has received approval for a third manufacturing facility for CASGEVY with our partner Lonza. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive and life-shortening disease. SCD patients report health-related quality of life scores well below the general population, and the lifetime health care costs in the U.S. of managing SCD for patients with recurrent VOCs is estimated between $4 and $6 million. SCD is an inherited blood disorder that affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or “sickled” red blood cells. The clinical hallmark of SCD is VOCs, which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires a lifetime of treatment and results in a reduced life expectancy. In the U.S., the median age of death for patients living with SCD is approximately 45 years. A cure for SCD today is a stem cell transplant from a matched donor, but this option is only available to a small fraction of patients living with SCD because of the lack of available donors. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and the lifetime health care costs in the U.S. of managing TDT are estimated between $5 and $5.7 million. TDT requires frequent blood transfusions and iron chelation therapy throughout a person’s life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. In the U.S., the median age of death for patients living with TDT is 37 years. Stem cell transplant from a matched donor is a curative option but is only available to a small fraction of people living with TDT because of the lack of available donors. About CASGEVYTM (exagamglogene autotemcel [exa-cel]) CASGEVYTM is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY (exagamglogene autotemcel) WHAT IS CASGEVY? CASGEVY is a one-time therapy used to treat people aged 12 years and older with: • sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs • beta thalassemia (β-thalassemia) who need regular blood transfusions CASGEVY is made specifically for each patient, using the patient’s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about CASGEVY? After treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). Your doctor will monitor this and give you treatment as required. The doctor will tell you when blood cell levels return to safe levels. You may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Talk to your physician regarding those possible side effects. Your healthcare provider may give you other medicines to treat your side effects. How will I receive CASGEVY? Your healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. It’s important to talk to your healthcare provider about the risks and benefits of all medicines involved in your treatment. After receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment. STEP 1: Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis). This entire process may happen more than once. Each time, it can take up to one week. During this step rescue cells are also collected and stored at the hospital. These are your existing blood stem cells and are kept untreated just in case there is a problem in the treatment process. If CASGEVY cannot be given after the conditioning medicine, or if the modified blood stem cells do not take hold (engraft) in the body, these rescue cells will be given back to you. If you are given rescue cells, you will not have any treatment benefit from CASGEVY. STEP 2: After they are collected, your blood stem cells will be sent to the manufacturing site where they are used to make CASGEVY. It may take up to 6 months from the time your cells are collected to manufacture and test CASGEVY before it is sent back to your healthcare provider. STEP 3: Shortly before your stem cell transplant, your healthcare provider will give you a conditioning medicine for a few days in hospital. This will prepare you for treatment by clearing cells from the bone marrow, so they can be replaced with the modified cells in CASGEVY. After you are given this medicine, your blood cell levels will fall to very low levels. You will stay in the hospital for this step and remain in the hospital until after the infusion with CASGEVY. STEP 4: One or more vials of CASGEVY will be given into a vein (intravenous infusion) over a short period of time. After the CASGEVY infusion, you will stay in hospital so that your healthcare provider can closely monitor your recovery. This can take 4-6 weeks, but times can vary. Your healthcare provider will decide when you can go home. What should I avoid after receiving CASGEVY? What are the possible or reasonably likely side effects of CASGEVY? The most common side effects of CASGEVY include: Your healthcare provider will test your blood to check for low levels of blood cells (including platelets and white blood cells). Tell your healthcare provider right away if you get any of the following symptoms: These are not all the possible side effects of CASGEVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of CASGEVY Talk to your healthcare provider about any health concerns. Please see full Prescribing Information including Patient Information for CASGEVY. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn , Facebook , Instagram , YouTube and X . (VRTX-GEN) Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Franco Locatelli, M.D., Ph.D. and Carmen Bozic, M.D., in this press release, and statements regarding expectations for the anticipated transformative, durable clinical benefits of CASGEVY, plans to continue working with reimbursement authorities to secure sustainable access for patients, including our expectations for progress in Canada and England, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com . You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. View source version on businesswire.com : https://www.businesswire.com/news/home/20241206536804/en/ CONTACT: Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.comMedia : mediainfo@vrtx.com or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS SOURCE: Vertex Pharmaceuticals Incorporated Copyright Business Wire 2024. PUB: 12/08/2024 12:52 PM/DISC: 12/08/2024 12:50 PM http://www.businesswire.com/news/home/20241206536804/enCHICAGO (AP) — Two-time NBA scoring champion Joel Embiid returned to the Philadelphia 76ers' starting lineup against the Chicago Bulls on Sunday. After missing his first seven shots and ambling deliberately in his left knee brace in the first quarter, the 2023 MVP went on a tear to propel the Sixers to a 108-100 win over the Chicago Bulls. Embiid connected on eight of his next 10 shots in the second quarter for his first 19 points of the game, which lifted Philadelphia to a 62-50 halftime lead. The Sixers stretched it to 19 before holding on for their fourth win in five games, and Embiid finished with 31. “I just got lucky and started making shots,” Embiid deadpanned when he talked to reporters almost 90 minutes after the game. “We just missed shots and we adjusted and we got them in.” Embiid, a seven-time All-Star, added 12 rebounds in his fifth game this season. The 7-foot center had missed the previous seven games because of knee injuries and a three-game suspension for pushing a sports columnist. Embiid finished slightly above his career average of nearly 27.8 points per game in 33 minutes. The Sixers don't play again until Friday thanks to the NBA Cup, so coach Nick Nurse planned to give his star ample work Sunday with a break and recovery time ahead. “All of a sudden he certainly caught fire there with a little bit of variety,” Nurse said. “I know a lot of it seemed like foul-line jumpers, which it was. He snuck in a roll or two and a couple of post-ups. It gave us a lot of confidence.” The Sixers trailed 33-23 after the first quarter. Behind Embiid and a 16-0 run in the second, they took the lead for good. Chicago got within four points twice in the fourth, but Philadelphia closed it out. “We guarded really well and we rebounded extremely well at both ends,” Nurse said. Tyrese Maxey got his first career triple-double as part of the winning formula and clicked with Embiid. Maxey finished with 25 points, 14 assists and 11 rebounds. “It was great, that's who he is,” Maxey said of Embiid. “After he got in the game it's easy, it was easier, man. There was a lot more space out there.” The All-Star trio of Embiid, Maxey and Paul George (12 points) played together for only the second game this season. “Obviously we've got the connection,” Embiid said. "We know when things are not going right, what we need to do. Now it's up to us to make the shots and the plays. “After that first quarter, it just felt like we needed to take more of an ownership as far as getting us back in the game. They're great players.” AP NBA: https://apnews.com/hub/nba

In conclusion, the 4.9% year-on-year growth in China's import and export trade in the first 11 months of this year demonstrates the resilience and vitality of China's foreign trade sector. With continued government support, technological advancement, and adaptive strategies, China is well-positioned to overcome challenges and achieve sustained growth in the global market.

Furthermore, the case has sparked discussions about the ethics of selective reduction and the societal pressures that lead to high-order multiple pregnancies. Some experts argue that the desire for large families and social expectations around fertility can contribute to risky and ethically questionable practices, such as pursuing fertility treatments without fully understanding the potential consequences.

Meet the 12 CFP Title Contenders: No. 12 Clemson

Here's how you can profit from BITCOIN MANIA